Background
Methods
Eligibility criteria
Data extraction
Statistical analysis
Results
Literature search
Study characteristics
First author, year | Region | Period | Study design | No. of cases/controlsa
| period | OR/RR | 95 % CI | Adjustment variablesb
| Outcome |
---|---|---|---|---|---|---|---|---|---|
Bean, 2011 | USA | 2001–2004 | CC | 566/552 | 1st month gestation | 1.07 | 0.58–1.98 | No | AVSD |
1.03 | 0.48–2.23 | ASD | |||||||
0.49 | 0.19–1.22 | VSD | |||||||
2nd/ 3rd month gestation | 0.64 | 0.19–2.21 | AVSD | ||||||
1.50 | 0.40–5.67 | ASD | |||||||
1.08 | 0.27–4.36 | VSD | |||||||
Botto, 2000 | USA | 1968–1980 | CC | 958/3029 | During pregnancy | 1.00 | 0.86–1.15 | No | CHDs |
Carmichael, 2003 | USA | 1987–1988 | CC | 207/481 | 1 month before to 3rd month gestation | 1.35 | 0.84–2.19 | B, D, F, K, I | TGA |
1.24 | 0.77–1.98 | TOF | |||||||
Cedergren, 2002 | Sweden | 1982–1996 | CC | 269/524 | Early pregnancy | 0.95 | 0.69–1.31 | No | CHDs |
Ewing, 1997 | USA | 1981–1989 | CC | 641/3549 | During pregnancy | 0.95 | 0.78–1.15 | No | VSD |
Fixler, 1998 | USA | CC | 89/82 | 3 months before to 3rd month gestation | 1.23 | 0.67–2.28 | No | CHDs | |
Grewal, 2008 | USA | 1999–2003 | CC | 323/700 | During pregnancy | 1.21 | 0.85–1.73 | No | Conotruncal defects |
Hobbs, 2010 | USA | 1998–2006 | CC | 572/363 | 1 month before to 3rd month gestation | 0.84 | 0.63–1.12 | No | CHDs |
Kuciene, 2009 | Lithuania | 1999–2005 | CC | 187/643 | During pregnancy | 1.39 | 0.87–2.25 | No | CHDs |
Larsen, 2011 | Denmark | 1996–2002 | Cohort | 477/ 86783 | During pregnancy | 1.24 | 0.97–1.59 | A, E, F, H, P | VSD |
0.89 | 0.66–1.21 | ASD | |||||||
Liu, 2013 | Canada | 2002–2010 | Cohort | 4123/22365 | During pregnancy | 1.88 | 1.74–2.04 | A, B, E, F, H, L, O | CHDs |
McDonald, 1992 | Canada | 1982–1984 | Cohort | 318/87389 | First trimester | 0.96 | 0.78–1.19 | A, B, D, F, G | CHD |
Malik, 2008 | USA | 1997–2002 | CC | 3067/3947 | 1 month before to 3rd month gestation | 0.93 | 0.85–1.03 | O | CHDs |
Martinez-Frias, 2004 | Spain | CC | 4705/4329 | During pregnancy | 0.96 | 0.78–1.19 | No | CHD | |
Mateja, 2012 | USA | 1996–2005 | CC | 237/948 | 3 months before pregnancy | 1.01 | 0.61–1.70 | No | CHDs |
O’Leary, 2013 | Australia. | 1983–2007 | Cohort | 277/61370 | During pregnancy | 1.40 | 0.91–1.98 | No | VSD |
2.86 | 1.22–4.93 | ASD | |||||||
2.01 | 0.58–4.07 | Conotruncal defects | |||||||
Smedts, 2009 | Netherlands | 2008 | CC | 276/324 | During pregnancy | 1.05 | 0.75–1.47 | No | CHDs |
Steinberger, 2002 | USA | 1981–1989 | CC | 237/3572 | During pregnancy | 1.00 | 0.10–7.70 | No | Single Ventricle |
Tikkanen, 1991 | Finland | 1982–1984 | CC | 573/1055 | First trimester | 1.29 | 1.05–1.59 | No | CHDs |
Tofs, 1999 | USA | 1991–1993 | CC | 80/605 | First trimester | 0.90 | 0.50–1.40 | No | CHDs |
1.30 | 0.70–2.40 | AVSD | |||||||
1.00 | 0.20–2.40 | TOF | |||||||
0.80 | 0.50–1.40 | ASD | |||||||
0.60 | 0.30–1.20 | VSD | |||||||
Van Beynum, 2010 | Netherlands | 1996–2005 | CC | 611/2401 | During pregnancy | 1.05 | 0.85–1.29 | No | CHDs |
Williams, 2004 | USA | 1968–1980 | CC | 122/3029 | 3 months before to 3rd month gestation | 1.02 | 0.71–1.47 | No | VSD |
Yauck, 2004 | USA | 1997–1999 | CC | 245/2780 | During pregnancy | 2.10 | 1.10–4.20 | No | CHDs |
Maternal alcohol consumption and CHDs
Subgroup analysis | No. of studies | Summary RR (95 % CIs) | P* | I2 (%) | P** |
---|---|---|---|---|---|
Summary pooled estimate | 23 | 1.11(0.96–1.29) | <0.001 | 88.8 | |
Design | 0.025 | ||||
Case-control | 19 | 1.00(0.95–1.06) | 0.260 | 16.0 | |
Cohort | 4 | 1.35(0.93–1.97) | <0.001 | 94.4 | |
Geographical region | 0.447 | ||||
North America | 15 | 1.10(0.89–1.36) | <0.001 | 92.1 | |
Europe | 7 | 1.09(0.99–1.19) | 0.449 | 0.0 | |
Australia | 1 | 1.69(1.23–2.33) | - | - | |
Period of pregnancy | 0.343 | ||||
Pre-pregnancy or until pregnancy is known | 6 | 0.95(0.88–1.04) | 0.426 | 0.0 | |
During pregnancy | 22 | 1.12(0.96–1.30) | <0.001 | 89.3 | |
Trimester 1 | 22 | 1.12(0.96–1.30) | <0.001 | 89.3 | |
Trimester 2 | 12 | 1.22(0.98–1.52) | <0.001 | 90.9 | |
Trimester 3 | 12 | 1.22(0.98–1.52) | <0.001 | 90.9 | |
Adjusted for smoking | 0.108 | ||||
Yes | 4 | 1.27(0.86–1.87) | <0.001 | 94.6 | |
No | 19 | 1.04(0.96–1.13) | 0.042 | 39.0 |
First author, year | Region | Period | Study design | No. of cases/controlsa
| period | Average dose (grams/d)b
| OR/RR | 95 % CI | Adjustment variablesc
| Outcome |
---|---|---|---|---|---|---|---|---|---|---|
Carmichael, 2003 | USA | 1987–1988 | CC | 207/481 | 1 month before to 3rd month gestation | 0 | 1.00 | 1.00–1.00 | B, D, F, K, I | Conotruncal defects |
0.9 | 1.20 | 0.80–1.70 | ||||||||
3 | 1.60 | 0.80–3.00 | ||||||||
Ewing, 1997 | USA | 1981–1989 | CC | 641/3549 | During pregnancy | 0 | 1.00 | 1.00–1.00 | No | VSD |
18 | 0.92 | 0.73–1.15 | ||||||||
48 | 0.91 | 0.71–1.78 | ||||||||
90 | 1.25 | 0.85–1.83 | ||||||||
Fixler, 1998 | USA | CC | 89/82 | 3 months before to 3rd month gestation | 0 | 1.00 | 1.00–1.00 | No | CHD | |
18 | 1.36 | 0.57–3.25 | ||||||||
42 | 1.20 | 0.48–3.02 | ||||||||
69 | 1.11 | 0.42–2.96 | ||||||||
Larsen, 2011 | Denmark | 1996–2002 | Cohort | 477/ 86783 | During pregnancy | 0 | 1.00 | 1.00–1.00 | A, E, F, H, P | VSD |
1.7 | 1.22 | 0.90–1.66 | ||||||||
3.4 | 1.38 | 0.83–2.28 | ||||||||
5.1 | 1.11 | 0.54–2.23 | ||||||||
0 | 1.00 | 1.00–1.00 | ASD | |||||||
1.7 | 1.03 | 0.73–1.47 | ||||||||
3.4 | 0.45 | 0.18–1.11 | ||||||||
5.1 | 0.66 | 0.27–1.62 | ||||||||
Martinez-Frias, 2004 | Spain | CC | 4705/4329 | During pregnancy | 0 | 1.00 | 1.00–1.00 | No | CHD | |
15 | 1.01 | 0.76–1.34 | ||||||||
24 | 1.66 | 0.35–8.73 | ||||||||
32 | 0.82 | 0.59–1.15 | ||||||||
72 | 1.99 | 0.32–15.60 | ||||||||
116 | 11.93 | 1.62–246.00 | ||||||||
McDonald, 1992 | Canada | 1982–1984 | Cohort | 318/87389 | First trimester | 0 | 1.00 | 1.00–1.00 | A, B, D, F, G | CHD |
2.9 | 0.91 | 0.70–1.20 | ||||||||
8.7 | 0.96 | 0.60–1.50 | ||||||||
17.9 | 1.24 | 0.70–2.20 | ||||||||
Williams, 2004 | USA | 1968–1980 | CC | 122/3029 | 3 months before to 3rd month gestation | 0 | 1.00 | 1.00–1.00 | No | VSD |
4.3 | 0.95 | 0.65–1.39 | ||||||||
12 | 1.22 | 0.43–3.45 | ||||||||
22 | 3.13 | 1.19–8.22 |